Neuroprotection for acute stroke making clinical trials work

Stroke

Volumn 30, Issue 1, 1999, Pages 180-182

  Muir, Keith W ^a   Grosset, Donald G ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Clinical trials; Lacunar infarction; Magnetic resonance imaging; Neuroprotection; Tomography, emission computed

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ALTEPLASE; APTIGANEL; CITICOLINE; ELIPRODIL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; LUBELUZOLE; RECEPTOR; TIRILAZAD; XENON;

BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN INFARCTION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STROKE;

EID: 0032908247     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.1.180     Document Type: Review

References (13)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Lees KR. Does neuroprotection improve stroke outcome? Lancet. 1998; 351:1447-1448.
3. Tamura A, Graham DI, McCulloch J, Teasdale GM. Focal cerebral ischaemia in the rat, 1: description of technique and early neuropathological consequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1981;1:53-60.
4. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
5. Grotta J. Lubeluzole treatment of acute ischemic stroke. Stroke. 1997;28: 2338-2346.
6. Clomethiazole Acute Stroke Study Collaborative Group. The Clomethiazole Acute Stroke Study (CLASS), II: results of a randomised controlled study of clomethiazole versus placebo in 545 acute stroke patients classified as total anterior circulation syndrome (TACS). Cerebrovasc Dis. 1997;7:19. Abstract.
7. Marchal G, Serrati C, Rioux P, Petit-Taboue MC, Viader F, de la Sayette V, le Doze F, Lochon P, Derlon JM, Orgogozo JM, Baron JC. PET imaging of cerebral perfusion and oxygen consumption in acute ischaemic stroke: relation to outcome. Lancet. 1993;341:925-927.
8. Baird AE, Donnan GA. Prognostic value of reperfusion during first 48 hours of ischaemic stroke. Lancet. 1993;342:236.
9. Hanson SK, Grotta JC, Rhoades H, Tran HD, Lamki LM, Barron BJ, Taylor WJ. Value of single-photon emission-computed tomography in acute stroke therapeutic trials. Stroke. 1993;24:1322-1329.
10. Warach S, Dashe JF, Edelman RR. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis. J Cereb Blood Flow Metab. 1996;16: 53-59.
11. Firlik AD, Rubin G, Yonas H, Wechsler LR. Relation between cerebral blood flow and neurologic deficit resolution in acute ischemic stroke. Neurology. 1998;51:177-182.
12. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne M-H. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
13. Steiner T, Bluhmki E, Kaste M, Toni D, Trouillas P, von Kummer R, Hacke W. The ECASS 3-hour cohort: secondary analysis of ECASS data by time stratification. Cerebrovasc Dis. 1998;8:198-203.